TrialSight is live — a clinical intelligence dashboard that gives pre-commercial biotech companies the same research capabilities as pharma giants, at a fraction of the cost.
The Problem
Pre-commercial biotech companies are flying blind. Enterprise clinical intelligence platforms from the likes of Citeline, Evaluate, and GlobalData cost $50,000–$200,000 per year. For a Series A biotech with 15 employees and a single pipeline asset, that's not a line item — it's a non-starter. So they improvise: manual PubMed searches, spreadsheet trackers, and gut-feel competitive analysis.
10 Public Data Sources, One Dashboard
TrialSight integrates 10 free, public biomedical data sources into a unified intelligence layer:
- >ClinicalTrials.gov — Trial registry, status, endpoints, enrollment
- >PubMed — Biomedical literature and abstracts
- >OpenAlex — Citation graphs and research impact metrics
- >NIH RePORTER — Federal grant funding and investigator data
- >openFDA — Adverse events, drug labels, approval history
- >USPTO — Patent filings and IP landscape
- >Europe PMC — European literature and preprints
- >SEC EDGAR — Public company filings and financial signals
- >ClinVar — Genetic variant and clinical significance data
- >UniProt — Protein sequence and function annotations
No proprietary databases. No six-figure license fees. Just structured access to the data that's already out there.
KOL Intelligence
TrialSight automatically identifies Key Opinion Leaders across any therapeutic area by cross-referencing publication records, citation networks, clinical trial involvement, and grant histories. Instead of hiring a medical affairs consultant to build a KOL map, you get one generated in seconds — with evidence trails.
AI Forecasting with Chorus
Every clinical program tracked in TrialSight receives a TrialSight Score (0–100) — a probability-weighted forecast of trial success powered by [Chorus](/projects/chorus), our 17-specialist AI ensemble. The score synthesizes trial design quality, historical comparator data, endpoint selection, enrollment trajectory, and competitive landscape signals. It's not a crystal ball, but it's a lot better than a slide deck and a prayer.
Built on Rising Sun Infrastructure
TrialSight isn't built from scratch — it's assembled from battle-tested components across the Rising Sun portfolio:
- >[AAASP](/projects/aaasp) — Multi-tenant agent orchestration for data ingestion pipelines
- >OpenMed — Biomedical data normalization and entity resolution
- >[Chorus](/projects/chorus) — Ensemble AI forecasting engine
- >[ProofStack](/projects/proofstack) — Provenance receipts for every data point and prediction
First Deployment: PABC
Our launch partner is the Pennsylvania Biotechnology Center (PABC) — home to 58+ biotech tenants ranging from early-stage startups to clinical-phase companies. TrialSight will be available as a shared resource across the PABC ecosystem, giving every tenant access to institutional-grade intelligence from day one.
Pricing
10–20x cheaper than incumbents. We're targeting the companies that enterprise vendors ignore — the ones actually doing the science.